Literature DB >> 30115224

Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Preserved Systolic Function.

Amgad Mentias1, Pejman Raeisi-Giglou1, Nicholas G Smedira1, Ke Feng1, Kimi Sato1, Oussama Wazni1, Mohamad Kanj1, Scott D Flamm1, Maran Thamilarasan1, Zoran B Popovic1, Harry M Lever1, Milind Y Desai2.   

Abstract

BACKGROUND: A high proportion of patients with hypertrophic cardiomyopathy (HCM) have evidence of late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR).
OBJECTIVES: This study sought to assess the incremental prognostic utility of LGE in patients with HCM.
METHODS: We studied 1,423 consecutive low-/intermediate-risk patients with HCM (age ≥18 years) with preserved left ventricular (LV) ejection fraction (mean age 66 ± 14 years, 60% men) who underwent transthoracic echocardiography (TTE) (including dimensions and LV outflow tract gradients) and CMR (including LGE as a % of LV mass) at our center between January 2008 and December 2015. The primary composite endpoint was sudden cardiac death (SCD) and appropriate implantable cardioverter-defibrillator discharge. The percent 5-year SCD risk score was calculated.
RESULTS: The mean 5-year SCD risk score was 2.3 ± 2.0. Mean maximal LV outflow tract gradient (TTE) was 70 ± 55 mm Hg (median 74 mm Hg [interquartile range (IQR): 10 to 67 mm Hg]); indexed LV mass and LGE (both on CMR) were 91 ± 10 g/m2 and 8.4 ± 12% (IQR: 0% to 19%); 50% had LGE on CMR. Of these, 458 were nonobstructive and 965 were obstructive (of which 686 were underwent myectomy). At 4.7 ± 2.0 years of follow-up, 60 (4%) met the composite endpoint. On quadratic spline analysis, LGE ≥15% was associated with increased risk of composite events. In the obstructive subgroup, on competing risk regression analysis, ≥15% LGE (subhazard ratio: 3.04 [95% confidence interval: 1.48 to 6.10]) was associated with a higher rate and myectomy (subhazard ratio: 0.44 [95% confidence interval: 0.20 to 0.76]) was associated with a lower rate of composite endpoints (both p < 0.01). Similarly, sequential addition of LGE ≥15% and myectomy to % 5-year SCD risk score improved the log likelihood ratios from -227.85 to -219.14 (chi-square 17) and to -215.14 (chi-square 8; both p < 0.01). Association of %LGE with composite events was similar even in myectomy and nonobstructive subgroups.
CONCLUSIONS: In low-/intermediate-risk adult patients with HCM (obstructive, myectomy, and nonobstructive subgroups) with preserved systolic function, %LGE was significantly associated with a higher rate of composite endpoint, providing incremental prognostic utility.
Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiac magnetic resonance; hypertrophic cardiomyopathy; risk stratification

Mesh:

Substances:

Year:  2018        PMID: 30115224     DOI: 10.1016/j.jacc.2018.05.060

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  35 in total

1.  Further Refining Risk in Hypertrophic Cardiomyopathy With Late Gadolinium Enhancement by CMR.

Authors:  Christopher M Kramer; Stefan Neubauer
Journal:  J Am Coll Cardiol       Date:  2018-08-21       Impact factor: 24.094

Review 2.  Advances in MRI Applications to Diagnose and Manage Cardiomyopathies.

Authors:  Ramya Vajapey; Brendan Eck; Wilson Tang; Deborah H Kwon
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-11-27

3.  Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry.

Authors:  Stefan Neubauer; Paul Kolm; Carolyn Y Ho; Raymond Y Kwong; Milind Y Desai; Sarahfaye F Dolman; Evan Appelbaum; Patrice Desvigne-Nickens; John P DiMarco; Matthias G Friedrich; Nancy Geller; Andrew R Harper; Petr Jarolim; Michael Jerosch-Herold; Dong-Yun Kim; Martin S Maron; Jeanette Schulz-Menger; Stefan K Piechnik; Kate Thomson; Cheng Zhang; Hugh Watkins; William S Weintraub; Christopher M Kramer
Journal:  J Am Coll Cardiol       Date:  2019-11-12       Impact factor: 24.094

Review 4.  Hypertrophic cardiomyopathy: an updated review on diagnosis, prognosis, and treatment.

Authors:  George Makavos; Chris Κairis; Maria-Eirini Tselegkidi; Theodoros Karamitsos; Angelos G Rigopoulos; Michel Noutsias; Ignatios Ikonomidis
Journal:  Heart Fail Rev       Date:  2019-07       Impact factor: 4.214

Review 5.  Evaluation of Hypertrophic Cardiomyopathy: Newer Echo and MRI Approaches.

Authors:  Manhal Habib; Sara Hoss; Harry Rakowski
Journal:  Curr Cardiol Rep       Date:  2019-06-26       Impact factor: 2.931

Review 6.  From Hypertrophy to Heart Failure: What Is New in Genetic Cardiomyopathies.

Authors:  Nosheen Reza; Kiran Musunuru; Anjali Tiku Owens
Journal:  Curr Heart Fail Rep       Date:  2019-10

7.  Long-term risk of sudden cardiac death in hypertrophic cardiomyopathy: a cardiac magnetic resonance outcome study.

Authors:  Simon Greulich; Andreas Seitz; Diana Herter; Fabian Günther; Sabine Probst; Raffi Bekeredjian; Meinrad Gawaz; Udo Sechtem; Heiko Mahrholdt
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2021-06-22       Impact factor: 6.875

Review 8.  Arrhythmic risk stratification by cardiac magnetic resonance tissue characterization: disclosing the arrhythmic substrate within the heart muscle.

Authors:  Aldostefano Porcari; Antonio De Luca; Chrysanthos Grigoratos; Federico Biondi; Giorgio Faganello; Giancarlo Vitrella; Gaetano Nucifora; Giovanni Donato Aquaro; Marco Merlo; Gianfranco Sinagra
Journal:  Heart Fail Rev       Date:  2022-01       Impact factor: 4.214

Review 9.  Hypertrophic Cardiomyopathy: Updates Through the Lens of Sports Cardiology.

Authors:  Bradley S Lander; Dermot M Phelan; Matthew W Martinez; Elizabeth H Dineen
Journal:  Curr Treat Options Cardiovasc Med       Date:  2021-05-25

Review 10.  CMR-Based Risk Stratification of Sudden Cardiac Death and Use of Implantable Cardioverter-Defibrillator in Non-Ischemic Cardiomyopathy.

Authors:  Laura Keil; Céleste Chevalier; Paulus Kirchhof; Stefan Blankenberg; Gunnar Lund; Kai Müllerleile; Christina Magnussen
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.